Science Translational Medicine· Borislav Dejanovic, Matthew D. Figley, Elizabeth Weisman, Beril Kiragasi, Frederick W. Gergits, Kelley Larson, Abigail Renoux, Raj Rajagovindan, Bhaumik Pandya, Jonathan Houze, Liyue Huang, Francois Gaudreault, Ryan O’Mara, Jade H. Clarkson, Marion T. Turnbull, Andreas Meier, Marco Colonna, Jessica Stromme, David Gray, Evan A. Thackaberry, Petra Kaufmann, Christian Mirescu·· 3 天前AI 评分25
用于阿尔茨海默病的口服小分子 TREM2 激动剂 VG-3927/SAR448851：临床前及首次人体评价
Preclinical and first-in-human evaluation of VG-3927/SAR448851, an oral small-molecule TREM2 agonist for Alzheimer’s disease
AI 导读
VG-3927/SAR448851 是一种用于阿尔茨海默病的口服小分子 TREM2 激动剂，研究对其开展了临床前及首次人体评价。该研究刊载于 Science Translational Medicine，所提供内容未披露具体研究设计、样本量或评价结果。
来源：Science Translational Medicine · science.org